We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bronchoalveolar Lavage Cell Pattern Determined for Diffuse Alveolar Hemorrhage

By LabMedica International staff writers
Posted on 11 Oct 2021
Diffuse alveolar hemorrhage (DAH) is a clinicopathological syndrome that describes the accumulation of intra-alveolar red blood cells originating from the alveolar capillaries. More...
DAH can induce severe respiratory failure.

Bronchoalveolar lavage (BAL) is an essential DAH diagnostic method. The BAL fluid (BALF) of DAH presents visually hemorrhagic and cytologically hemosiderin-laden macrophages. Antithrombotic therapy (AT) is known to be one of the causes of DAH, and other etiologies can induce DAH during AT.

Respiratory Specialists at the Osaka Police Hospital (Osaka-City, Japan) conducted a retrospective cohort study of patients admitted between October 2008 and July 2020. The study aim was to identify prognostic factors of DAH, especially bronchoalveolar lavage fluids (BALF) cell pattern. In the study, DAH was defined by the following criteria: Clinical and radiological presentation that was compatible with a diagnosis of DAH, and Bronchoalveolar lavage fluids (BALF) that was macroscopically bloody or cytologically contained hemosiderin-burden macrophages. Infection was confirmed when the specific microorganism was identified by culture or serological test. The team included 68 patients in their analysis with a median age was 75 (72–80) years, and 49 (72%) patients were male.

The investigators reported that in-hospital mortality was 26.5%. Variables associated with in-hospital death were neutrophils percentage in BALF ≥ 44.5% [Odds Ratio (OR) 16.0, 95% confidence interval (CI) 4.33–58.9)], lymphocytes percentage in BALF < 14% (OR 7.44, 95% CI 2.11–26.2), idiopathic DAH (OR 0.31, 95% CI 0.10–0.95), oxygen flow ≥ 4L/min (OR 3.90, 95% CI 1.20–12.6), and estimated glomerular filtration rate < 60 mL/min (OR 5.00, 95%CI 1.29–19.4). In-hospital mortality was significantly higher in patients with neutrophils percentage ≥ 44.5% and lymphocytes percentage < 14% compared with patients with neutrophils percentage < 44.5% and lymphocytes percentage ≥ 14%.

The authors concluded that a higher neutrophils percentage in BALF was found to be significantly associated with in-hospital mortality. On the other hand, a higher lymphocytes percentage in BALF was correlated with lower mortality. The study was published on September 9, 2021 in the journal BMC Pulmonary Medicine.

Related Links:
Osaka Police Hospital


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.